b
cell
respons
examin
nine
patient
infect
pandem
influenza
viru
patient
vari
cours
sever
diseas
case
rang
mild
diseas
rapid
viral
clearanc
within
day
onset
symptom
sever
case
shed
viru
sever
week
requir
hospit
ventil
support
major
patient
treat
antivir
drug
diagnos
confirm
pandem
rtpcr
serolog
patient
neutral
titer
serum
antibodi
time
blood
collect
summari
clinic
patient
data
shown
tabl
major
sampl
obtain
around
onset
symptom
except
particularli
sever
case
sampl
done
symptom
onset
antigenspecif
plasmablast
appear
transient
peripher
blood
vaccin
influenza
vaccin
brokstad
et
al
bernasconi
et
al
sasaki
et
al
wrammert
et
al
kinet
appear
persist
ongo
infect
remain
unclear
analyz
magnitud
specif
plasmablast
respons
blood
sampl
taken
within
week
onset
clinic
symptom
pandem
influenza
viru
infect
use
virusspecif
elispot
assay
possibl
show
signific
number
pandem
plasmablast
blood
infect
patient
wherea
none
detect
cohort
healthi
volunt
fig
b
cell
also
readili
detect
sever
week
symptom
onset
sever
case
fig
c
illustr
total
iggsecret
cell
half
cell
produc
antibodi
bound
pandem
influenza
viru
moreov
plasmablast
specif
ha
occur
frequenc
virusspecif
cell
fig
c
specif
like
critic
protect
patient
also
rel
high
frequenc
plasmablast
form
antibodi
bound
past
season
influenza
strain
fig
c
recombin
ha
previou
annual
strain
base
overal
frequenc
pandem
cell
like
cell
bind
strain
overlap
popul
crossreact
none
induc
plasmablast
cell
bound
recombin
ha
strain
vaccin
find
demonstr
influenzaspecif
human
plasmablast
continu
gener
throughout
ongo
infect
fairli
high
proport
cell
make
antibodi
also
crossreact
previou
annual
influenza
strain
analyz
specif
breadth
neutral
capac
plasmablast
use
singlecel
pcr
amplifi
heavi
light
chain
variabl
region
gene
individu
sort
cell
defin
cell
fig
e
wrammert
et
al
smith
et
al
gene
clone
express
mab
cell
antibodi
screen
reactiv
elisa
threshold
score
antibodi
specif
influenza
antigen
empir
determin
base
two
standard
deviat
greater
background
level
bind
evid
naiv
b
cell
antibodi
fig
antibodi
gener
fashion
bound
pandem
fig
f
one
third
antibodi
reactiv
ha
fig
g
fig
subnanomolar
avid
base
surfac
plasmon
reson
analys
fig
b
per
donor
basi
mab
bound
purifi
pandem
virion
rang
virusspecif
antibodi
bound
recombin
ha
rang
conclud
virusspecif
plasmablast
readili
detect
pandem
influenza
viru
infect
virusspecif
human
mab
effici
gener
cell
plasmablast
specif
induc
ongo
immun
respons
learn
origin
b
cell
activ
pandem
infect
consist
frequenc
plasmablast
secret
antibodi
bind
annual
influenza
strain
elispot
analys
fig
c
major
pandem
antibodi
also
crossreact
season
influenza
virus
fig
b
fact
elisa
one
third
antibodi
bind
prepandem
strain
lower
concentr
pandem
strain
suggest
higher
avid
bind
comparison
plasmablast
induc
annual
strain
pandem
could
bind
pandem
influenza
fig
b
propos
crossreact
pandem
cell
deriv
activ
memori
cell
origin
specif
past
influenza
immun
origin
antigen
sin
fashion
base
induct
plasmablast
express
intracellular
ongo
immun
respons
brokstad
et
al
bernasconi
et
al
sasaki
et
al
smith
et
al
wrammert
et
al
assum
plasmablast
result
ongo
infect
vaccin
respons
readi
detect
clonal
expans
mean
frequenc
cell
six
patient
support
view
base
sequenc
similar
fig
c
sinc
discoveri
somat
mutat
appreci
mutat
progress
accumul
variabl
gene
repeat
immun
mckean
et
al
thu
gain
insight
origin
pandem
respons
compar
somat
mutat
frequenc
plasmablast
present
infect
plasmablast
respons
pcr
strategi
allow
isol
either
igg
iga
transcript
identifi
igg
iga
plasmablast
patient
similar
plasmablast
induc
annual
vaccin
wrammert
et
al
fourth
booster
vaccin
anthrax
variabl
gene
novel
cell
five
six
patient
harbor
high
number
somat
mutat
averag
per
patient
fig
fig
patient
mutat
accumul
significantli
primari
igg
plasmablast
respons
anthrax
vaccinia
small
pox
vaccin
iggposit
memori
b
cell
histor
data
averag
gene
student
test
p
zheng
et
al
koelsch
et
al
wrammert
et
al
fig
c
fig
b
igg
memori
cell
sequenc
previous
publish
anoth
group
averag
gene
de
wildt
et
al
interestingli
patient
em
outlier
fig
sever
infect
tabl
mutat
accumul
significantli
lower
frequenc
igg
control
fig
p
suggest
uniqu
circumst
lowlevel
lack
primari
respons
detail
sequenc
characterist
pandem
plasmablast
provid
tabl
though
base
limit
number
patient
frequent
crossreact
high
number
somat
mutat
support
model
mani
plasmablast
induc
pandem
infect
aros
crossreact
memori
b
cell
high
frequenc
haspecif
antibodi
abl
neutral
viru
vitro
total
fig
neutral
antibodi
could
categor
two
distinct
group
neutral
antibodi
display
hemagglutin
inhibit
hai
activ
hai
b
neutral
antibodi
hai
activ
indic
bound
site
ha
activ
site
interestingli
antibodi
latter
type
predomin
respons
fig
specif
reminisc
antibodi
recent
discov
broadli
neutral
epitop
found
ha
stalk
rather
locat
ha
globular
head
typic
neutral
antibodi
ekiert
et
al
sui
et
al
importantli
five
antibodi
inde
similar
specif
includ
antibodi
clonal
pair
donor
five
antibodi
bind
high
affin
strain
includ
vaccin
past
yr
pandem
strain
highli
pathogen
avian
influenza
strain
fig
b
fig
addit
five
antibodi
crosscompet
similar
epitop
overlap
hai
antibodi
fig
antibodi
competit
inhibit
commerci
antibodi
refer
bind
ha
stalk
region
okuno
et
al
four
five
antibodi
encod
hallmark
gene
ekiert
et
al
sui
et
al
verifi
ha
stalk
reactiv
five
antibodi
test
bind
variant
predict
affect
stalk
epitop
crystal
structur
bind
pattern
compar
prototyp
stalk
antibodi
mab
sui
et
al
fig
b
variant
singl
residu
mutat
stalk
region
transient
express
cell
fac
analysi
show
five
antibodi
bound
variant
test
level
quit
similar
crystal
structur
gener
defin
epitop
thu
half
neutral
surpris
antibodi
induc
pandem
infect
bound
conserv
critic
epitop
ha
stalk
comparison
none
strainspecif
antibodi
previous
isol
annual
vaccin
pandem
reactiv
unpublish
data
frequenc
pandemicinduc
stemreact
antibodi
versu
annual
vaccin
significantli
greater
chisquar
test
p
specif
rare
seen
human
memori
b
cell
corti
et
al
phagedisplay
librari
sui
et
al
observ
support
idea
vaccin
might
develop
preferenti
target
ha
stalk
thu
provid
broad
protect
mani
influenza
strain
remain
neutral
antibodi
hai
therefor
bound
ha
globular
head
base
crosscompetit
analys
antibodi
fell
two
group
bind
nonoverlap
region
ha
head
includ
fig
b
fig
inde
use
spontan
escap
mutant
select
found
mab
bind
sa
region
ha
globular
head
unpublish
data
thu
proxim
base
competit
assay
fig
predict
antibodi
bind
near
sasb
region
includ
broadli
reactiv
antibodi
bind
pandem
strain
common
annual
strain
identifi
human
kraus
et
al
xu
et
al
mice
manicassami
et
al
notabl
three
five
ha
antibodi
induc
pandem
infect
also
broadli
reactiv
variou
strain
fig
b
one
novel
antibodi
antibodi
react
strongli
pandem
strain
well
recent
vaccin
strain
fig
b
fig
precis
epitop
antibodi
bind
appear
quit
uniqu
access
whole
virion
recombin
ha
suggest
epitop
quaternari
natur
final
two
antibodi
crossreact
inhibit
hemagglutin
recent
vaccin
strain
react
strongli
pandem
strain
antibodi
fig
b
fig
mab
bind
past
vaccin
strain
higher
avid
pandem
studi
underway
precis
identifi
epitop
neutral
antibodi
studi
two
neutral
antibodi
highli
specif
pandem
strain
alon
fig
b
fig
includ
low
avid
antibodi
show
slight
neutral
capac
vitro
effect
neutral
pandem
influenza
conclud
experi
surpris
neutral
plasmablast
isol
pandem
influenza
infect
broadli
crossreact
multipl
influenza
strain
distinct
interest
develop
monoclon
antibodi
use
therapeut
set
select
three
repres
antibodi
set
identifi
detail
function
analysi
vitro
fig
c
vivo
fig
fig
includ
antibodi
specif
activ
site
ha
molecul
wherea
bind
stalk
region
furthermor
highli
specif
pandem
wherea
display
broadli
crossreact
bind
fig
b
function
activ
multipl
recent
older
strain
fig
c
antibodi
highli
effect
provid
prophylact
protect
infect
lethal
dose
mouseadapt
pandem
balbc
mice
fig
moreov
three
antibodi
effect
therapeut
even
administ
late
h
lethal
challeng
infect
well
mice
symptomat
success
treat
mice
far
h
postinfect
unpublish
data
infect
mice
alreadi
show
measur
weight
loss
revers
administr
antibodi
demonstr
therapeut
potenti
even
onset
diseas
viral
clearanc
analyz
mice
treat
h
infect
fig
earli
day
antibodytr
mice
exhibit
log
reduct
viral
titer
titer
continu
declin
day
viru
undetect
present
low
level
untreat
mice
perish
day
wherea
treat
mice
clear
infect
detect
viru
day
final
show
activ
sever
current
older
season
influenza
strain
vitro
fig
c
also
test
vivo
antigen
distinct
influenza
strain
experi
mice
treat
mab
intraperiton
h
infect
lethal
dose
either
pandem
influenza
either
two
common
influenza
laboratori
strain
show
protect
antigen
distinct
influenza
strain
illustr
fig
highli
specif
pandem
protect
effect
infect
conclus
antibodi
character
herein
show
promis
develop
broadli
reactiv
therapeut
agent
pandem
influenza
viru
well
major
influenza
strain
find
provid
insight
human
b
cell
respons
pandem
influenza
viru
strain
uniqu
genet
composit
pandem
influenza
viru
meant
rel
young
cohort
probabl
littl
preexist
specif
antibodymedi
immun
viru
infect
brockwellstaat
et
al
dawood
et
al
garten
et
al
hancock
et
al
thu
two
sourc
b
cell
could
contribut
respons
newli
recruit
naiv
b
cell
preexist
memori
b
cell
bound
epitop
conserv
past
season
strain
pandem
strain
theoriz
predomin
activ
latter
preexist
memori
cell
account
observ
high
frequenc
neutral
antibodi
habind
antibodi
major
crossreact
season
strain
fig
c
group
influenza
strain
includ
ha
sever
observ
support
conjectur
convincingli
particularli
high
frequenc
crossreact
antibodi
overal
high
level
somat
mutat
found
particularli
among
variabl
gene
crossreact
cell
fig
fig
fact
elisa
antibodi
crossreact
one
third
antibodi
bound
past
annual
viral
antigen
lower
concentr
suggest
higher
avid
past
influenza
strain
current
pandem
viru
crossreact
cell
bind
higher
affin
pandem
strain
also
highest
frequenc
variablegen
mutat
fig
b
antibodi
broadli
crossreact
among
highli
mutat
clone
fig
b
propos
mani
cell
specif
crossreact
epitop
present
annual
influenza
strain
underw
affin
matur
adapt
infect
pandem
viru
support
conjectur
corti
et
al
first
demonstr
natur
occur
ha
memori
b
cell
could
isol
blood
peopl
recent
immun
annual
vaccin
outbreak
pandem
natur
studi
screen
ebvtransform
memori
cell
line
thu
preclud
determin
precis
frequenc
stalkreact
b
cell
howev
antibodi
estim
quit
rare
occur
one
thousand
one
hundr
influenzabind
b
cell
vari
individu
contrast
show
plasmablast
activ
infect
highli
novel
pandem
influenza
strain
substanti
increas
target
ha
stalk
region
epitop
total
influenzaspecif
antibodi
half
neutral
antibodi
fig
fact
specif
antibodi
isol
studi
crossreact
past
influenza
strain
collect
data
describ
support
model
diverg
virus
conserv
critic
region
function
elicit
higher
proport
crossreact
neutral
antibodi
thu
although
activ
plasmablast
rel
patient
could
analyz
detail
monoclon
antibodi
level
proffer
proper
immunogen
longsought
develop
paninfluenza
vaccin
might
possibl
interestingli
highli
specif
antibodi
deriv
patient
sever
diseas
cours
persist
viral
shed
sever
week
addit
variabl
gene
plasmablast
patient
lowest
averag
number
somat
mutat
fig
b
outlier
fig
b
collect
uniqu
specif
pandem
low
level
somat
mutat
unusu
sever
diseas
absenc
predispos
condit
suggest
patient
may
mount
primari
immun
respons
pandem
influenza
infect
complet
lack
preexist
immun
may
contribut
sever
diseas
observ
patient
contrast
activ
broadli
crossneutr
memori
b
cell
immun
experi
annual
strain
might
contribut
less
sever
diseas
infect
patient
pandem
notabl
discrep
patient
serum
mn
titer
sever
diseas
frequenc
plasmablast
express
neutral
antibodi
tabl
fig
exampl
patient
em
despit
worst
diseas
cours
greatest
hai
mn
serum
titer
may
caus
time
infect
day
allow
full
seroconvers
presenc
highli
potent
antibodi
whose
activ
less
like
titer
highli
specif
natur
respons
patient
may
contribut
advantag
ultim
better
target
epitop
pandem
strain
contrast
patient
rel
low
hai
mn
serum
titer
highest
frequenc
broadli
neutral
antibodi
less
sever
diseas
cours
one
possibl
sampl
patient
done
peak
serolog
respons
anoth
possibl
high
frequenc
potent
antibodi
memori
b
cell
compart
may
result
rapid
resolut
infect
preclud
develop
high
serolog
respons
third
possibl
despit
broader
protect
stalkreact
antibodi
whole
less
potent
rapidli
titrat
highli
specif
antibodi
ha
globular
head
variou
possibl
signific
interest
studi
futur
final
report
develop
larg
panel
human
mab
induc
pandem
infect
prophylact
therapi
polyclon
mab
success
use
rsv
rabi
hepat
b
varicella
case
influenza
mab
shown
provid
prophylact
therapeut
protect
mice
anim
model
reuman
et
al
sweet
et
al
palladino
et
al
renegar
et
al
passiv
transfer
matern
antibodi
human
also
shown
confer
protect
puck
et
al
sever
antibodi
isol
broad
neutral
capac
vitro
diverg
influenza
strain
show
potent
prophylact
therapeut
activ
use
treat
mice
lethal
infect
influenza
antibodi
could
provid
much
need
pandem
therapeut
treat
sever
case
influenza
protect
highrisk
popul
conclus
analys
mab
induc
pandem
infect
indic
frequent
activ
broadli
reactiv
b
cell
propos
cell
memori
cell
origin
caus
crossreact
conserv
function
import
epitop
true
import
character
efficaci
pandem
vaccin
induc
similarli
crossprotect
respons
studi
approv
emori
univers
univers
chicago
columbia
univers
institut
review
board
emori
irb
u
c
irb
cu
irb
patient
clinic
inform
detail
tabl
work
sampl
infect
patient
perform
design
facil
emori
univers
peripher
blood
mononuclear
cell
pbmc
isol
use
vacutain
tube
bd
wash
resuspend
pb
fc
immedi
use
frozen
subsequ
analysi
plasma
sampl
save
frozen
medium
dimethyl
sulfoxid
subsequ
analysi
pandem
influenza
viru
provid
rj
webbi
st
jude
children
hospit
memphi
tn
influenza
viru
stock
use
assay
freshli
grown
egg
prepar
purifi
previous
describ
wrammert
et
al
hemagglutin
inhibit
activ
determin
use
turkey
red
blood
cell
lampir
biolog
laboratori
previous
describ
wrammert
et
al
purchas
inactiv
prepar
prospectani
technogen
ltd
includ
follow
anew
asolomon
vaccin
test
includ
vaccin
chiron
vaccin
limit
formul
sanofi
pasteur
inc
recombin
ha
protein
provid
influenza
reagent
resourc
wwwinfluenzareagentresourceorg
cdc
recombin
ha
biodefens
emerg
infect
research
repositori
wwwbeiresourcesorg
recombin
ha
abrevig
purchas
sino
biolog
direct
elispot
enumer
number
either
total
iggsecret
pandem
vaccinespecif
plasmablast
present
pbmc
sampl
essenti
done
previous
describ
crotti
et
al
brief
elispot
filter
plate
millipor
coat
overnight
either
optim
amount
purifi
pandem
virion
recombin
ha
pandem
influenza
vaccin
dilut
pb
goat
ig
invitrogen
plate
wash
block
incub
rpmi
contain
fc
h
purifi
extens
wash
pbmc
sort
plasmablast
ad
plate
dilut
seri
incub
h
plate
wash
pb
follow
pb
contain
tween
incub
biotinyl
antihuigg
antibodi
invitrogen
incub
h
room
temperatur
wash
plate
incub
avidindhrp
conjug
vector
laboratori
final
develop
use
aec
substrat
ethylcarbazol
sigmaaldrich
develop
plate
scan
analyz
use
autom
elispot
counter
cellular
technolog
ltd
analyt
flow
cytometri
analysi
perform
whole
blood
lysi
erythrocyt
fix
pfa
live
cell
sort
singl
cell
sort
perform
purifi
pbmc
use
either
facsvantag
ariaii
cell
sorter
system
follow
antibodi
analyt
cell
sort
cytometri
purchas
bd
except
purchas
ebiosci
percp
percp
asc
gate
isol
cell
flow
cytometri
data
analyz
use
flowjo
softwar
identif
antibodi
variabl
region
gene
done
essenti
previous
describ
smith
et
al
wardemann
et
al
wrammert
et
al
brief
singl
asc
sort
pcr
plate
contain
rnase
inhibitor
promega
vh
gene
cell
amplifi
rtpcr
nest
pcr
reaction
use
cocktail
primer
specif
igg
iga
use
primer
set
detail
smith
et
al
sequenc
gener
recombin
antibodi
restrict
site
incorpor
pcr
primer
particular
variabl
junction
gene
vh
gene
amplifi
singl
cell
clone
express
vector
previous
describ
wardemann
et
al
wrammert
et
al
smith
et
al
antibodi
sequenc
deposit
genbank
access
no
avail
genbankemblddbj
heavylight
chain
plasmid
cotransfect
cell
line
express
antibodi
purifi
protein
sepharos
antibodi
protein
gener
studi
provid
limit
quantiti
upon
request
antibodi
induc
plasmablast
variabl
gene
amplifi
singlecel
rtpcr
use
primer
set
pcr
condit
previous
publish
wrammert
et
al
smith
et
al
variabl
gene
determin
use
inhous
analysi
softwar
compar
immunogent
v
gene
dataset
imgt
search
engin
ehrenmann
et
al
lefranc
et
al
background
mutat
rate
method
baseexchang
per
base
sequenc
base
sequenc
constant
region
gene
segment
comparison
made
histor
data
previous
publish
zheng
et
al
wrammert
et
al
duti
et
al
mdck
cell
grown
plate
densiti
next
day
cell
wash
pb
dilut
viru
ad
dme
incub
h
mix
everi
min
cell
wash
pb
overlay
media
contain
agaros
seakem
antibiot
uml
penicillin
mgml
streptomycin
bsa
sigmaaldrich
tpcktrypsin
sigmaaldrich
cell
incub
h
fix
pfa
min
agaros
plug
remov
cell
stain
crystal
violet
etoh
min
remov
crystal
violet
solut
plate
dri
use
count
plaqu
well
assay
mdck
cell
prepar
next
day
mab
threefolddilut
pfu
viru
dme
incub
equal
volum
dilut
mab
h
plaqu
assay
plaqu
count
final
concentr
antibodi
reduc
plaqu
pfu
score
determin
mdck
cell
grown
plate
densiti
next
day
cell
wash
pb
dilut
virus
dme
ad
well
incub
h
incub
cell
wash
pb
dme
contain
antibiot
uml
penicillin
mgml
streptomycin
bsa
sigmaaldrich
tpcktrypsin
sigmaaldrich
ad
cell
incub
h
supernat
incub
equal
volum
pbswash
turkey
red
blood
cell
rockland
immunochem
min
four
replic
perform
dilut
complet
agglutin
score
ha
viru
titer
calcul
reedmuench
method
mn
assay
viru
dme
incub
threefolddilut
antibodi
h
cell
wash
incub
media
describ
hai
assay
h
mn
titer
determin
final
concentr
mab
complet
inhibit
infect
whole
viru
recombin
ha
vaccinespecif
elisa
perform
start
concentr
viru
recombin
ha
dilut
vaccin
previous
describ
wrammert
et
al
brief
microtit
plate
coat
live
viru
strain
total
hau
total
viru
per
well
recombin
ha
protein
standard
variou
elisa
assay
common
highaffin
antibodi
similar
affin
bind
characterist
viru
strain
includ
plate
plate
develop
absorb
control
reach
od
unit
goat
igg
goat
iperoxidaseconjug
jackson
immunoresearch
laboratori
use
detect
bind
recombin
antibodi
follow
develop
horseradish
peroxidas
substrat
biorad
laboratori
absorb
measur
micropl
reader
invitrogen
affin
estim
calcul
nonlinear
regress
analysi
curv
eight
dilut
antibodi
ugml
use
graphpad
prism
hai
titer
determin
previous
describ
wrammert
et
al
brief
sampl
serial
dilut
pb
well
vbottom
plate
hau
determin
incub
turkey
rbc
absenc
serum
live
egggrown
viru
ad
well
min
room
temperatur
turkey
rbc
rockland
immunochem
suspend
pb
bsa
ad
well
plate
shaken
manual
addit
min
room
temperatur
serum
titer
minimum
effect
concentr
read
base
final
dilut
button
observ
competit
elisa
perform
inhibit
bind
biotinyl
antibodi
nhscoupl
thermo
fisher
scientif
halfmaxim
bind
concentr
molar
excess
purifi
antibodi
comparison
differ
antibodi
base
percentag
absorb
valu
antibodi
score
inhibit
detect
done
use
streptavidinhrp
describ
elisa
assay
fulllength
ha
gene
codonoptim
eukaryot
cell
express
clone
vector
obtain
construct
sui
et
al
mutant
deriv
construct
quikchang
method
stratagen
fulllength
wild
type
mutant
express
plasmid
transfect
transient
cell
lipofectamin
invitrogen
h
transfect
cell
harvest
immunostain
antiha
antibodi
control
human
mab
sui
et
al
ferret
serum
dilut
incub
transfect
cell
h
cell
wash
three
time
pb
contain
bsa
fitclabel
goat
igg
thermo
fisher
scientif
fitclabel
goat
igg
bethyl
ad
cell
incub
min
cell
wash
bind
antibodi
cell
analyz
use
bd
facscalibur
cellquest
softwar
kinet
interact
mab
recombin
ha
protein
determin
surfac
plasmon
reson
spr
use
instrument
antibodi
immobil
sensor
chip
amin
coupl
recombin
ha
concentr
rang
nm
hbsep
buffer
inject
immobil
antibodi
refer
cell
surfac
run
buffer
hbsep
appli
sensor
surfac
regener
singl
inject
mm
naoh
experi
recombin
ha
histag
immobil
nta
sensor
chip
target
densiti
respons
unit
antibodi
concentr
rang
nm
hbsp
buffer
inject
immobil
recombin
ha
refer
cell
surfac
follow
dissoci
phase
experi
perform
triplic
kinet
analysi
inject
refer
cell
surfac
inject
buffer
subtract
data
associ
rate
ka
dissoci
rate
kd
equilibrium
dissoci
constant
kd
calcul
align
curv
fit
bind
model
use
biaevalu
softwar
antibodi
could
determin
mab
bind
recombin
ha
protein
baculoviru
suffici
well
spr
avid
mab
antibodi
neutral
infect
vitro
estim
scatchard
plot
analys
elisa
data
shown
parenthes
femal
balbc
mice
use
challeng
studi
mice
inocul
intranas
highli
pathogen
mouseadapt
pandem
influenza
viru
influenza
viru
mous
adapt
pandem
viru
serial
passag
mice
five
gener
use
herein
virus
determin
vivo
infect
variou
viru
concentr
accord
method
reed
muench
experi
conduct
accord
ethic
procedur
polici
approv
emori
univers
institut
anim
care
use
committe
determin
prophylact
efficaci
mab
mice
treat
intraperiton
mgkg
bodi
weight
specif
mab
h
later
mice
challeng
one
mous
adapt
influenza
virus
use
studi
mice
monitor
daili
sign
morbid
mortal
bodi
weight
chang
regist
daili
period
mice
lost
initi
bodi
weight
sacrif
accord
institut
anim
care
use
committe
guidelin
determin
therapeut
efficaci
mab
mice
challeng
mouseadapt
pandem
viru
variou
time
infect
h
mice
treat
intraperiton
mgkg
bodi
weight
specif
mab
mice
monitor
daili
bodi
weight
chang
regist
daili
describ
data
collect
graph
use
ms
excel
graphpad
prism
softwar
efficaci
therapeut
challeng
experi
evalu
analysi
varianc
use
graphpad
prism
softwar
fig
show
bind
characterist
control
mab
fig
show
bind
characterist
neutral
mab
fig
show
analysi
pandem
plasmablast
somat
mutat
fig
show
experi
demonstr
therapeut
control
pandem
viral
titer
lung
mab
treatment
tabl
provid
detail
characterist
concern
variabl
gene
sequenc
clone
pandem
induc
plasmablast
onlin
supplement
materi
avail
http
